Epigenomic characterization of locally advanced anal cancer: A radiation therapy oncology group 98-11 specimen study

Diseases of the Colon and Rectum

Volumn 57, Issue 8, 2014, Pages 941-957

  Siegel, Erin M ^a   Eschrich, Steven ^a   Winter, Kathryn ^b   Riggs, Bridget ^a   Berglund, Anders ^a   Ajidahun, Abidemi ^a   Simko, Jeff ^c   Moughan, Jennifer ^b   Ajani, Jaffer ^d   Magliocco, Anthony ^a   Elahi, Abul ^a   Hoffe, Sarah ^a   Shibata, David ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c Biospecimen Resource Radiation Therapy Oncology Group   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal cancer; Epigenetic; Genome wide array; Locally advanced anal cancer; Methylation

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ANUS CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TERTIARY HEALTH CARE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DNA METHYLATION; EPIGENOMICS; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 84904861330     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0000000000000160     Document Type: Article

References (108)

1. Eng C. Anal cancer: current and future methodology. Cancer Invest. 2006;24: 535-544. (Pubitemid 44576408)
2. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer. 2008;113(10 suppl): 2892-2900.
3. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101: 281-288. (Pubitemid 38890830)
4. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013;31: 1569-1575.
5. Surveillance, Epidemiology, and End Results Program. SER cancer statistics factsheets: anal cancer. http://seer.cancer.gov/statfacts/html/anus. html. Accessed May 6, 2014.
6. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299: 1914-1921. (Pubitemid 351574921)
7. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTO G 98-11 phase II trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30: 4344-4351.
8. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14: 516-524.
9. Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30: 1941-1948.
10. Wietfeldt ED, Thiele J. Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg. 2009;22: 127-135.
11. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128: 683-692. (Pubitemid 46273572)
12. Bird A. The essentials of DNA methylation. Cell. 1992;70: 5-8.
13. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6: 1083-1098.
14. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112: 293-299.
15. Shivapurkar N, Sherman ME, Stastny V, et al. Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol. 2007;107: 549-553. (Pubitemid 350160871)
16. Yang N, Nijhuis ER, Volders HH, et al. Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol. 2010;32: 131-143.
17. Delmas AL, Riggs BM, Pardo CE, et al. WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis. 2011;32: 1625-1633.
18. Zhang J, Martins CR, Fansler ZB, et al. DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res. 2005;11: 6544-6549. (Pubitemid 41338993)
19. Hernandez JM, Siegel EM, Riggs B, et al. DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. PLoS One. 2012;7: e50533.
20. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 2006;16: 383-393. (Pubitemid 43327509)
21. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6: 692-702.
22. Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics. 2013;14: 293.
23. Kunnev D, Ivanov I, Ionov Y. Par-3 partitioning defective 3 homolog (C. elegans) and androgen-induced prostate proliferative shutoff associated protein genes are mutationally inactivated in prostate cancer cells. BMC Cancer. 2009;9: 318.
24. Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev. 2010;20: 41-50.
25. Yang XX, Sun JZ, Li FX, et al. Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol. 2012;18: 2719-2726.
26. Chung MT, Sytwu HK, Yan MD, et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol. 2009;112: 301-306.
27. Marsit CJ, McClean MD, Furniss CS, Kelsey KT. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer. 2006;119: 1761-1766. (Pubitemid 44356831)
28. Perry AS, O'Hurley G, Raheem OA, et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int J Cancer. 2013;132: 1771-1780.
29. Castellana B, Escuin D, Peiró G, et al. ASPN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas. J Cancer. 2012;3: 175-183.
30. Zhao R, Zhang R, Li W, et al. Genome-wide DNA methylation patterns in discordant sib pairs with alcohol dependence. Asia Pac Psychiatry. 2013;5: 39-50.
31. Melle C, Ernst G, Scheibner O, et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res. 2007;6: 306-315. (Pubitemid 46173682)
32. Maines MD, Mayer RD, Erturk E, Huang TJ, Disantagnese A. The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma-pH and cofactor-specific increase in activity. J Urol. 1999;162: 1467-1472. (Pubitemid 29428620)
33. Hellman K, Alaiya AA, Becker S, et al. Differential tissuespecific protein markers of vaginal carcinoma. Br J Cancer. 2009;100: 1303-1314.
34. Barone E, Cenini G, Sultana R, et al. Lack of p53 decreases basal oxidative stress levels in the brain through upregulation of thioredoxin-1, biliverdin reductase-A, manganese superoxide dismutase, and nuclear factor kappa-B. Antioxid Redox Signal. 2012;16: 1407-1420.
35. Florczyk U, Golda S, Zieba A, Cisowski J, Jozkowicz A, Dulak J. Overexpression of biliverdin reductase enhances resistance to chemotherapeutics. Cancer Lett. 2011;300: 40-47.
36. Chan JY, Li L, Miao J, Cai DQ, Lee KK, Chui YL. Differential expression of a novel gene BRE (TNFRSF1A modulator/BRCC45) in response to stress and biological signals. Mol Biol Rep. 2010;37: 363-368.
37. Kollmann K, Heller G, Schneckenleithner C, et al. A kinaseindependent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24: 167-181.
38. McLaughlin-Drubin ME, Park D, Munger K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci USA. 2013;110: 16175-16180.
39. Griguer CE, Cantor AB, Fathallah-Shaykh HM, et al. Prognostic relevance of cytochrome Coxidase in primary glioblastoma multiforme. PLoS One. 2013;8: e61035.
40. Sen S, Kawahara B, Chaudhuri G. Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: implications for breast cancer. Free Radic Biol Med. 2013;57: 210-220.
41. Aichler M, Elsner M, Ludyga N, et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol. 2013;230: 410-419.
42. Lecoeur H, Borgne-Sanchez A, Chaloin O, et al. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. Cell Death Dis. 2012;3: e282.
43. Kang JU, Koo SH, Kwon KC, Park JW. Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int J Oncol. 2010;37: 327-335.
44. Hong SM, Omura N, Vincent A, et al. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2012;18: 700-712.
45. Kim J, Min SY, Lee HE, Kim WH. Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinoma. Int J Cancer. 2012;130: 817-826.
46. Bennett KL, Lee W, Lamarre E, et al. HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. Genes Chromosomes Cancer. 2010;49: 319-326.
47. Arai E, Chiku S, Mori T, et al. Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis. 2012;33: 1487-1493.
48. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene. 2004;23: 3737-3748. (Pubitemid 38725687)
49. Weichert W, Röske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98: 604-610. (Pubitemid 351214528)
50. Gu Y, Yang P, Shao Q, et al. Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol Lett. 2013;5: 452-458.
51. Liu M, Chen J, Hu L, et al. HORMAD2/CT46.2, a novel cancer/testis gene, is ectopically expressed in lung cancer tissues. Mol Hum Reprod. 2012;18: 599-604.
52. Gao F, Shi L, Russin J, et al. DNA methylation in the malignant transformation of meningiomas. PLoS One. 2013;8: e54114.
53. Strathdee G, Holyoake TL, Sim A, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res. 2007;13: 5048-5055. (Pubitemid 47502069)
54. Raff AB, Woodham AW, Raff LM, et al. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013;87: 6062-6072.
55. Backen AC, Cole CL, Lau SC, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer. 2007;96: 1544-1548. (Pubitemid 46762949)
56. Chan HW, Miller JS, Moore MB, Lutz CT. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol. 2005;175: 5966-5974. (Pubitemid 41508081)
57. Suryo Rahmanto Y, Dunn LL, Richardson DR. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark-from iron metabolism to tumorigenesis. Oncogene. 2007;26: 6113-6124. (Pubitemid 47414377)
58. Davalos V, Moutinho C, Villanueva A, et al. Dynamic epigenetic regulation of the microRNA -200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2012;31: 2062-2074.
59. Wiklund ED, Gao S, Hulf T, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One. 2011;6: e27840.
60. Zidar N, Boštjančič E, Gale N, et al. Down-regulation of microRNA s of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck: hallmark of epithelial-mesenchymal transition. Hum Pathol. 2011;42: 482-488.
61. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle (Georgetown, Tex). 2012;11: 4390-4401.
62. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466: 765-768.
63. Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One. 2013;8: e62857.
64. Hoverter NP, Ting JH, Sundaresh S, Baldi P, Waterman ML. A WNT/p21 circuit directed by the C-clamp, a sequence-specific DNA binding domain in TCFs. Mol Cell Biol. 2012;32: 3648-3662.
65. Mori Y, Olaru AV, Cheng Y, et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer. 2011;18: 465-478.
66. Ongenaert M, Wisman GB, Volders HH, et al. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med Genomics. 2008;1: 57.
67. Yang N, Eijsink JJ, Lendvai A, et al. Methylation markers for CCNA 1 and C13ORF18 are strongly associated with highgrade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers Prev. 2009;18: 3000-3007.
68. Hu X, Guo J, Zheng L, et al. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res. 2013;11: 240-250.
69. Licciulli S, Maksimoska J, Zhou C, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem. 2013;288: 29105-29114.
70. Schelhaas M, Shah B, Holzer M, et al. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raftindependent endocytosis. PLoS Pathog. 2012;8: e1002657.
71. Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res. 2002;8: 589-595. (Pubitemid 34193981)
72. Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatinresistance related genes in head and neck squamous cell carcinoma. Int J Cancer. 2010;126: 437-449.
73. Wang X, Huang CJ, Yu GZ, et al. Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer. Hum Pathol. 2013.
74. Ren P, Zhang JG, Xiu L, Yu ZT. Clinical significance of phospholipase A2 group IIA (PLA 2G2A) expression in primary resected esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2013;17: 752-757.
75. Schweikert EM, Devarajan A, Witte I, et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012;19: 1549-1560.
76. Waerner T, Gardellin P, Pfizenmaier K, Weith A, Kraut N. Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. Cell Growth Differ. 2001;12: 201-210. (Pubitemid 32678233)
77. Fang J, Rhyasen G, Bolanos L, et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 2012;120: 858-867.
78. Narayan G, Murty VV. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol. 2010;6: 1643-1652.
79. Costello LC, Zou J, Desouki MM, Franklin RB. Evidence for changes in RREB-1, ZIP3, and Zinc in the early development of pancreatic adenocarcinoma. J Gastrointest Cancer. 2012;43: 570-578.
80. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR- 143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. 2013;32: 2576-2585.
81. Steinbrecher A, Méplan C, Hesketh J, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev. 2010;19: 2958-2968.
82. Takata Y, Kristal AR, Santella RM, et al. Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One. 2012;7: e38612.
83. Goodrich JM, Basu N, Franzblau A, Dolinoy DC. Mercury biomarkers and DNA methylation among Michigan dental professionals. Environ Mol Mutagen. 2013;54: 195-203.
84. Fonseca-Camarillo G, Yamamoto-Furusho JK. Gene expression of solute carrier family 9 (sodium/hydrogen exchanger) 3, (SLC9A3) is downregulated in patients with ulcerative colitis. Inflamm Bowel Dis. 2012;18: 1197-1198.
85. Galvan A, Frullanti E, Anderlini M, et al. Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. Carcinogenesis. 2013;34: 2767-2773.
86. Rousset R, Fabre S, Desbois C, Bantignies F, Jalinot P. The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene. 1998;16: 643-654. (Pubitemid 28062344)
87. Lee HS, Lee DC, Park MH, et al. STMN2 is a novel target of beta-catenin/TCF-mediated transcription in human hepatoma cells. Biochem Biophys Res Commun. 2006;345: 1059-1067. (Pubitemid 43776512)
88. Flanagan JM, Popendikyte V, Pozdniakovaite N, et al. Intra- and interindividual epigenetic variation in human germ cells. Am J Hum Genet. 2006;79: 67-84. (Pubitemid 43927378)
89. Best A, Dagliesh C, Ehrmann I, Kheirollahi-Kouhestani M, Tyson-Capper A, Elliott DJ. Expression of Tra2 β in cancer cells as a potential contributory factor to neoplasia and metastasis. Int J Cell Biol. 2013;2013: 843781.
90. Shu J, Jelinek J, Chang H, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res. 2006;66: 5077-5084. (Pubitemid 43844929)
91. An CH, Kim SS, Kang MR, et al. Frameshift mutations of ATBF1, WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability. Pathology. 2010;42: 583-585.
92. Lv Z, Zhang M, Bi J, Xu F, Hu S, Wen J. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol. 2006;125: 740-746.
93. Lin PC, Giannopoulou EG, Park K, et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia. 2013;15: 373-383.
94. Delgado-Cruzata L, Hruby GW, Gonzalez K, et al. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol. 2012;31: 187-192.
95. Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One. 2010;5: e12334.
96. Kim YJ, Yoon HY, Kim JS, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer. 2013;133: 1135-1142.
97. Guo W, Zhu T, Dong Z, Cui L, Zhang M, Kuang G. Decreased expression and aberrant methylation of Gadd45G is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Clin Exp Metastasis. 2013;30: 977-992.
98. Colacino JA, Dolinoy DC, Duffy SA, et al. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. PLoS One. 2013;8: e54742.
99. Poage GM, Butler RA, Houseman EA, et al. Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer. Cancer Res. 2012;72: 2728-2737.
100. Guerrero-Setas D, Pérez-Janices N, Blanco-Fernandez L, et al. RASF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Mod Pathol. 2013;26: 1111-1122.
101. Lendvai Á, Johannes F, Grimm C, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics. 2012;7: 1268-1278.
102. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13: 767-779.
103. Lee J, Yoon YS, Chung JH. Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines. Gynecol Oncol. 2008;109: 270-274.
104. Lee EJ, Jo M, Rho SB, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer. 2009;124: 287-297.
105. van der Meide WF, Snellenberg S, Meijer CJ, et al. Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol. 2011;123: 116-122.
106. Leonard SM, Wei W, Collins SI, et al. Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis. 2012;33: 1286-1293.
107. Fragoso-Ontiveros V, María Alvarez-García R, Contreras-Paredes A, et al. Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis. Virology. 2012;432: 81-90.
108. Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC. Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions. Radiat Oncol. 2011;6: 134.